Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 8/20 | 0.61 |
| ▸ | MERTK | Q12866 | 2/20 | 0.46 |
| ▸ | ERN1 | O75460 | 7/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58723 | 0.91 | ACVRL1 (0.61) | ACVRL1MERTKERN1FLT3TYRO3 | |
| SCHEMBL58166 | 0.81 | ACVRL1 (0.61) | ACVRL1MERTKFLT3TYRO3AXL | |
| SCHEMBL60171 | 0.81 | ACVRL1 (0.48) | ACVRL1MERTKFLT3TYRO3AXL | |
| SCHEMBL58355 | 0.81 | ACVRL1 (0.61) | ACVRL1MERTKFLT3AXL | |
| SCHEMBL65127 | 0.81 | ACVRL1 (0.65) | ACVRL1MERTKFLT3AXL | |
| SCHEMBL14700075 | 0.81 | KDR (0.44) | ACVRL1MERTKFLT3TYRO3AXL | |
| SCHEMBL5031587 | 0.81 | ACVRL1 (0.47) | ACVRL1MERTKFLT3TYRO3AXL | |
| SCHEMBL90887 | 0.80 | ACVRL1 (0.59) | ACVRL1MERTKFLT3AXL | |
| SCHEMBL58436 | 0.80 | ACVRL1 (0.59) | ACVRL1MERTKFLT3AXL | |
| SCHEMBL58839 | 0.80 | ACVRL1 (0.47) | ACVRL1MERTKFLT3TYRO3AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129379-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | CDK4, CDKL4, MKI67 | ACVRL1 941/4885MERTK 1749/4885ERN1 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.